# Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease

> **NCT02097056** · PHASE4 · COMPLETED · sponsor: **Eisai Korea Inc.** · enrollment: 171 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Donepezil HCL

## Key facts

- **NCT ID:** NCT02097056
- **Lead sponsor:** Eisai Korea Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2016-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02097056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02097056, "Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02097056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*